Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders

Abstract

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.

1 . A method of treating presbyopia in a human patient, comprising topically administering to an eye of the human patient in need thereof (i) a dosage of from 0.4 mg to 0.6 mg of phentolamine mesylate and (ii) only one additional agent that improves visual performance, wherein the additional agent is selected from the group consisting of pilocarpine and a pharmaceutically acceptable salt thereof, to thereby treat the presbyopia, wherein the dosage of phentolamine mesylate is administered to the eye no more than once per day. 
     
     
         2 . The method of  claim 1 , wherein the additional agent is pilocarpine hydrochloride. 
     
     
         3 . The method of  claim 1 , wherein the additional agent is topically administered to the eye of the patient in an amount ranging from about 0.1 mg to about 0.5 mg. 
     
     
         4 . The method of  claim 2 , wherein the additional agent is topically administered to the eye of the patient in an amount ranging from about 0.1 mg to about 0.5 mg. 
     
     
         5 . The method of  claim 1 , wherein the method provides a therapeutic effect against presbyopia for a duration of at least 6 hours. 
     
     
         6 . The method of  claim 4 , wherein the method provides a therapeutic effect against presbyopia for a duration of at least 6 hours. 
     
     
         7 . The method of  claim 1 , wherein the method provides a therapeutic effect against presbyopia for a duration of at least 12 hours. 
     
     
         8 . The method of  claim 4 , wherein the method provides a therapeutic effect against presbyopia for a duration of at least 12 hours. 
     
     
         9 . (canceled) 
     
     
         10 . The method of  claim 4 , wherein the method results in an improvement in near-vision visual acuity characterized by at least a two-line improvement in the patient's vision measured using a vision chart. 
     
     
         11 . (canceled) 
     
     
         12 . The method of  claim 4 , wherein the method results in an improvement in near-vision visual acuity characterized by at least a three-line improvement in the patient's vision measured using a vision chart. 
     
     
         13 . The method of  claim 1 , wherein the patient experiences an increase in eye redness of no more than one grade measured using the CCLRU Redness Grading Scale compared to the patient's level of eye redness without receiving said dosage of phentolamine mesylate. 
     
     
         14 . The method of  claim 4 , wherein the patient experiences an increase in eye redness of no more than one grade measured using the CCLRU Redness Grading Scale compared to the patient's level of eye redness without receiving said dosage of phentolamine mesylate. 
     
     
         15 - 18 . (canceled) 
     
     
         19 . The method of  claim 1 , wherein the patient experiences the effect of having a pupil diameter of less than 2.6 mm in the eye that received said dosage when measured under photopic conditions. 
     
     
         20 . The method of  claim 4 , wherein the patient experiences the effect of having a pupil diameter of less than 2.6 mm in the eye that received said dosage when measured under photopic conditions. 
     
     
         21 . The method of  claim 1 , wherein as a result of the administering, the patient experiences the effect of having a pupil diameter of less than 2.4 mm in the eye that received said dosage when measured under photopic conditions. 
     
     
         22 . The method of  claim 4 , wherein as a result of the administering, the patient experiences the effect of having a pupil diameter of less than 2.4 mm in the eye that received said dosage when measured under photopic conditions. 
     
     
         23 - 26 . (canceled) 
     
     
         27 . The method of  claim 1 , wherein the dosage of phentolamine mesylate is administered as an eye drop. 
     
     
         28 . The method of  claim 4 , wherein the dosage of phentolamine mesylate is administered as an eye drop. 
     
     
         29 . The method of  claim 1 , wherein the dosage of phentolamine mesylate is administered at or near the bedtime of the patient. 
     
     
         30 . The method of  claim 4 , wherein the dosage of phentolamine mesylate is administered at or near the bedtime of the patient. 
     
     
         31 . The method of  claim 29 , wherein the additional agent is administered to said eye of the patient after administering to said eye of the patient the dosage of phentolamine mesylate. 
     
     
         32 . The method of  claim 30 , wherein the additional agent is administered to said eye of the patient after administering to said eye of the patient the dosage of phentolamine mesylate. 
     
     
         33 . The method of  claim 1 , wherein the dosage of phentolamine mesylate is 0.5 mg. 
     
     
         34 - 37 . (canceled) 
     
     
         38 . The method of  claim 1 , wherein the additional agent is a nitric acid salt of pilocarpine. 
     
     
         39 . The method of  claim 1 , wherein the additional agent is topically administered to the eye of the patient in an amount ranging from (a) about 0.1 mg to about 0.5 mg or (b) about 0.5 mg to about 0.75 mg.